Long-Term Response and Possible Cure of Patients With B-Cell Malignancies With Dose-Escalated Rituximab

Rituximab (R), a chimeric monoclonal antibody targeting CD20 antigen on B-cells, has become a standard of care in the treatment of B-cell malignancies, most often in conjunction with cytotoxic chemotherapy. Activity has been demonstrated in many subtypes of B-cell lymphoma, including diffuse large c...

Descripción completa

Detalles Bibliográficos
Autores principales: Jacobs, Lauren M., Wiernik, Peter H., Dutcher, Janice P., Muxi, Pablo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5298442/
https://www.ncbi.nlm.nih.gov/pubmed/28203581
http://dx.doi.org/10.1177/2324709617691307

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5298442/
https://www.ncbi.nlm.nih.gov/pubmed/28203581
http://dx.doi.org/10.1177/2324709617691307

Ejemplares similares